Eugeroics: Difference between revisions
>Discount Pharmacologist m Discount Pharmacologist moved page Talk:Eugeroics to Eugeroics |
>Unity Implement PW style & formatting standards |
||
| Line 1: | Line 1: | ||
Eugeroics (originally, "eugrégorique" or "eugregoric"), also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of | {{headerpanel|{{stub}}}} | ||
'''Eugeroics''' (originally, "eugrégorique" or "eugregoric"), also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of [[psychoactive substances]] that promote wakefulness and alertness. The best-known member of this class is [[modafinil]]. | |||
Eugeroics are medically indicated for the treatment of certain sleep disorders including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA). They are also often prescribed off-label for the treatment of EDS in idiopathic hypersomnia, a rare and often debilitating sleep disorder which currently has no official treatments approved by the Food and Drug Administration (FDA). | |||
[[Subjective effects]] include [[wakefulness]], [[focus enhancement]], [[motivation enhancement]], and [[stimulation]]. They share many effects with stimulants; however, they do not produce much [[euphoria]] and have less abuse potential. They are sometimes used as a substitute for prescription stimulants to aid in studying and productivity. | |||
Eugeroics have low abuse potential. Chronic use does not produce physical dependence, but may produce psychological dependence in some individuals.{{citation needed}} Studies indicate they are physiologically well-tolerated;{{citation needed}} however, it should be noted that the long-term effects are not well-studied as they are relatively new. | |||
It is highly advised to use [[harm reduction practices]] if using these substances. | |||
==Examples== | ==Examples== | ||
| Line 21: | Line 31: | ||
*Selective H<sub>3</sub> receptor antagonists/inverse agonists | *Selective H<sub>3</sub> receptor antagonists/inverse agonists | ||
*Selective orexin receptor agonists | *Selective orexin receptor agonists | ||
==See also== | |||
*[[Responsible use]] | |||
*[[Stimulants]] | |||
==External links== | |||
*[https://en.wikipedia.org/wiki/Eugeroics Eugeroics (Wikipedia)] | |||
==References== | |||
{{references}} | |||
Revision as of 06:03, 29 November 2021
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Eugeroics (originally, "eugrégorique" or "eugregoric"), also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of psychoactive substances that promote wakefulness and alertness. The best-known member of this class is modafinil.
Eugeroics are medically indicated for the treatment of certain sleep disorders including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA). They are also often prescribed off-label for the treatment of EDS in idiopathic hypersomnia, a rare and often debilitating sleep disorder which currently has no official treatments approved by the Food and Drug Administration (FDA).
Subjective effects include wakefulness, focus enhancement, motivation enhancement, and stimulation. They share many effects with stimulants; however, they do not produce much euphoria and have less abuse potential. They are sometimes used as a substitute for prescription stimulants to aid in studying and productivity.
Eugeroics have low abuse potential. Chronic use does not produce physical dependence, but may produce psychological dependence in some individuals.[citation needed] Studies indicate they are physiologically well-tolerated;[citation needed] however, it should be noted that the long-term effects are not well-studied as they are relatively new.
It is highly advised to use harm reduction practices if using these substances.
Examples
Marketed
- Armodafinil (Nuvigil)
- Modafinil (Provigil)
- Solriamfetol (Sunosi)
- Pitolisant (Wakix)
Discontinued
Never marketed
- Flmodafinil (CRL-40,940)
- Fluorafinil (CRL-40,941)
- Fluorenol
- Methylbisfluoromodafinil
In development
- Selective H3 receptor antagonists/inverse agonists
- Selective orexin receptor agonists
See also
External links
References
 |
This article does not cite enough references. You can help by adding some. |